Business Context and Reporting Period
This Form 8-K is a current report filed by Rexahn Pharmaceuticals, Inc. (not Opus Genetics, Inc.) on June 15, 2007, regarding events occurring on June 11, 2007. The filing reports the election of a new director to the Company's Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is the election of Dr. Freddie Ann Hoffman to the Board of Directors to fill the vacancy left by the expiration of Dr. Young Soon Park's term. Dr. Hoffman brings significant experience as a pediatric hematology-oncologist, former CEO of HeteroGeneity, LLC, and former senior official at the FDA and National Cancer Institute.
Compensation and Governance Details
- Stock Options: Dr. Hoffman received an initial grant of 20,000 options to purchase common stock at an exercise price of $1.40 per share (fair market value on the grant date).
- Vesting Schedule: The initial options fully vest on June 11, 2008.
- Future Compensation: She will receive an additional 20,000 options annually upon re-election and a board meeting fee of $1,000 per meeting.
- Arrangements: The filing states there are no undisclosed arrangements or understandings regarding her election.
Investor Verification Checklist
- Verify the correct registrant name is Rexahn Pharmaceuticals, Inc., as the input metadata referenced Opus Genetics, Inc.
- Confirm the exercise price of $1.40 per share for the 20,000 options granted to Dr. Hoffman.
- Review the Company's non-employee director compensation policy for details on future annual option grants.
- Check subsequent filings for any financial impact related to the stock-based compensation expense.